Comparative Pharmacology
Head-to-head clinical analysis: CARAC versus INGENOL MEBUTATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARAC versus INGENOL MEBUTATE.
CARAC vs INGENOL MEBUTATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carac (fluorouracil) is a fluorinated pyrimidine antimetabolite that inhibits thymidylate synthase, thereby interfering with DNA synthesis and repair. It also incorporates into RNA, disrupting RNA processing and function.
Ingenol mebutate is a macrocyclic diterpene ester that induces rapid, mitochondria-dependent cell death (necrosis) in dysplastic keratinocytes upon topical application. It also activates protein kinase C (PKC) isoforms, specifically PKCδ, leading to mitochondrial dysfunction and release of pro-apoptotic factors. Additionally, it stimulates a local immune response via neutrophil-mediated oxidative burst and antibody-dependent cellular cytotoxicity.
Apply 0.5% cream twice daily for 2-4 weeks to affected area; maximum single dose 1g, not exceed 60g per course.
0.05% gel applied topically to the lesion once daily for 2 consecutive days per treatment course; repeat after 3 weeks if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 20 minutes for the parent drug, but the active metabolite 5-fluorouracil (5-FU) has a half-life of 8–20 minutes; due to rapid metabolism, prolonged exposure occurs with continuous infusion.
Terminal half-life approximately 18–24 hours; supports twice-daily application for actinic keratosis treatment.
Primarily metabolized via dihydropyrimidine dehydrogenase (DPD) in the liver; ~10% excreted unchanged in urine; remaining metabolites eliminated renally (including CO2 and urea).
Primarily hepatobiliary excretion into feces; minimal renal elimination (<1% unchanged).
Category C
Category C
Topical Antineoplastic
Topical Antineoplastic